Skip to main content

Lung Cancer

Lung Cancer
Repotrectinib, an Investigational TKI, Elicits Responses in Patients with Advanced NSCLC and ROS1 Alterations
Wayne Kuznar
Wayne Kuznar
Read More
Lung Cancer
BLU-667, Selective RET Inhibitor, Demonstrates Antitumor Activity in NSCLC with RET Fusion
Wayne Kuznar
Wayne Kuznar
Read More
FDA Approvals, Lung Cancer, Select Drug Profiles
Opdivo-Yervoy First Immunotherapy Combo Approved for First-Line Therapy of Patients with Metastatic NSCLC
Read More
FDA Approvals, Lung Cancer, Select Drug Profiles
Tecentriq Approved as First-Line Therapy for Metastatic NSCLC with High PD-L1 Expression
Read More
FDA Approvals, Lung Cancer, Select Drug Profiles
Opdivo plus Yervoy and Limited Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression
Read More
FDA Approvals, Lung Cancer, Select Drug Profiles
Tecentriq plus Avastin First Immunotherapy Regimen Approved for Metastatic Hepatocellular Carcinoma
Read More
FDA Approvals, Lung Cancer, Select Drug Profiles
FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation
Read More
Lung Cancer
Adjuvant Osimertinib a Practice-­Changing Treatment in Early-Stage NSCLC with EGFR Mutation
Wayne Kuznar
Wayne Kuznar
Read More
Lung Cancer
Durvalumab plus Chemotherapy New Standard of Care for Extensive-Stage Small-Cell Lung Cancer
Phoebe Starr
Phoebe Starr
Read More
Lung Cancer
Capmatinib Shows Activity in MET-Amplified Non–Small-Cell Lung Cancer
Wayne Kuznar
Wayne Kuznar
Read More
Page 4 of 5
Results 31 - 40 of 44